Loading
Aspirin roughly halves bowel cancer in Lynch syndrome, and a dose trial is defining how little is needed. Most carriers are still not prescribed it; the task is to fix prescribing.
Aspirin roughly halves bowel cancer in Lynch syndrome, as CAPP2 showed with 600 mg, and CaPP3 is comparing 100, 300 and 600 mg, yet most carriers are still not prescribed it. This idea is an implementation programme: guideline update, an automatic recommendation at diagnosis and registry tracking of prescription and adherence, so that nearly every carrier is on the right dose within three years. The evidence exists; the gap is practice. The test is a registry-based before-and-after study with regional stepped rollout. Being tested at scale, it addresses the bottlenecks Inherited risk is mostly unidentified and Prevention we already have is not deployed, and links to aspirin for cancer prevention.
People with Lynch syndrome should be offered daily aspirin, which roughly halves bowel cancer risk with a delayed and durable effect. Whether a lower dose (as tested in CAPP3) is as effective, and whether the finding extends to the general population, are separate questions.
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Mismatch-repair deficient (MSI-high) colorectal cancer.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Prevention we already have is not deployed.
Shares CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years, Aspirin for cancer prevention and adjuvant therapy, Mismatch-repair deficient (MSI-high) colorectal cancer.